+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gamma Globulin Therpeautic Agent Market by Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Application (Autoimmune Disease, Primary Immune Deficiency, Secondary Immune Deficiency), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Gamma Globulin Therpeautic Agent Market by Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Application (Autoimmune Disease, Primary Immune Deficiency, Secondary Immune Deficiency), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Gamma Globulin Therpeautic Agent Market by Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Application (Autoimmune Disease, Primary Immune Deficiency, Secondary Immune Deficiency), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136980
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Gamma globulin, commonly referred to as immunoglobulin, has emerged as an indispensable immunotherapeutic intervention, offering passive immunity transfer to patients with compromised or dysregulated immune systems. As a biologic preparation derived from pooled human plasma, gamma globulin therapies address a range of clinical needs, spanning from primary immune deficiency disorders to autoimmune pathologies. With established efficacy in conditions such as chronic inflammatory demyelinating polyneuropathy and Kawasaki disease, these therapeutics continue to demonstrate expanding potential across new indications.

Recent advancements in fractionation technologies and viral inactivation methods have significantly enhanced the safety and purity of immunoglobulin products. These improvements, coupled with growing investments in manufacturing capacity, have facilitated broader availability and reduced production costs. Despite these gains, stakeholders face ongoing challenges including plasma supply limitations, stringent regulatory requirements, and heterogeneous reimbursement policies across key markets.

This executive summary provides a concise yet comprehensive overview of critical factors influencing the gamma globulin therapeutic landscape. It outlines transformative shifts reshaping the industry, assesses the implications of forthcoming regulatory and tariff updates, and offers strategic recommendations designed to support sustainable growth and innovation.

Unveiling the Transformative Shifts Propelling Gamma Globulin Therapy as Precision Medicine Advances Redefine Treatment Paradigms and Access Models

The gamma globulin therapeutics landscape is undergoing a paradigm shift driven by precision medicine approaches and technological breakthroughs. As genomic profiling and biomarker‐guided patient stratification become integral to clinical practice, immunoglobulin treatments are being tailored to individual immune response patterns. This move toward personalized dosing regimens has optimized therapeutic efficacy, while novel subcutaneous and recombinant immunoglobulin formulations have improved patient adherence and convenience.

Alongside clinical innovation, strategic collaborations between pharmaceutical developers and technology companies are accelerating the integration of digital health solutions. Remote monitoring platforms enable real‐time tracking of treatment outcomes and adverse events, fostering proactive care adjustments. In parallel, home administration models are gaining traction, supported by training programs for patients and caregivers. This shift not only enhances quality of life but also alleviates the burden on hospital infrastructure. Consequently, market participants are redefining value propositions by combining cutting‐edge biologic innovations with patient‐centric care delivery modalities.

Evaluating the Far Reaching Cumulative Impact of 2025 United States Tariffs on Gamma Globulin Therapeutics Supply Chains and Cost Structures

The implementation of new United States tariffs in 2025 is poised to exert notable pressure on gamma globulin supply chains and cost structures. Raw materials, including plasma derivatives and excipients sourced from international partners, may encounter higher import duties, elevating procurement expenses for manufacturers. In response, several industry players are exploring localized plasma collection initiatives and strategic alliances with domestic suppliers to mitigate tariff‐induced price escalations.

Moreover, the ripple effect of increased production costs is likely to impact downstream distribution channels, potentially translating into higher pricing for hospital pharmacies, retail outlets, and home care providers. Payers and health systems may seek to renegotiate reimbursement frameworks, emphasizing cost‐efficient administration routes and outcome‐based contracting. To navigate this complex environment, companies are adopting dynamic scenario planning and reassessing global sourcing strategies, ensuring resilience in the face of regulatory shifts and cross‐border trade challenges.

Unlocking Gamma Globulin Market Dynamics Through Segmentation Across Product Types Applications Administration Distribution Channels and End Users

Insight into gamma globulin market dynamics deepens when analyzed through multiple segmentation lenses. Examining product types reveals distinct growth drivers for hyperimmune globulin, prized for its elevated antibody titers, versus standard immunoglobulin, which maintains broad clinical utility. When evaluating application segments, the increasing prevalence of autoimmune diseases underscores demand for immunomodulatory solutions, while untreated primary and secondary immune deficiencies create enduring clinical need.

Further, delivery modalities are reshaping market adoption, as subcutaneous administration enables convenient at‐home dosing and intravenous formats remain the standard in acute care settings, complemented by intramuscular options in specific indications. The end‐user landscape spans hospital environments, where specialist teams manage complex regimens, to home care programs offering patient autonomy, and outpatient clinics facilitating routine administration. Concurrently, distribution channels-ranging from hospital pharmacies to online platforms and traditional retail pharmacies-are evolving to meet diverse stakeholder requirements. By integrating these segmentation insights, industry participants can refine portfolio strategies, align with stakeholder preferences, and unlock new avenues for targeted growth.

Deep Diving into Regional Trends Driving Adoption of Gamma Globulin Therapeutics Across the Americas Europe Middle East Africa and Asia Pacific

Across the Americas, strong plasma donation networks and favorable reimbursement policies have established the region as a cornerstone for immunoglobulin production and consumption. North American markets, in particular, benefit from robust infrastructure and high treatment uptake, while Latin American nations are witnessing incremental access improvements funded by public health initiatives.

In Europe, Middle East, and Africa, regulatory harmonization efforts are gradually streamlining product approvals, yet disparities in healthcare funding models continue to influence market penetration. Countries with established national immunization programs leverage centralized procurement to negotiate volume‐based pricing, whereas emerging markets in the Middle East and Africa are investing in domestic plasma fractionation capacity to reduce import dependence.

The Asia‐Pacific region is characterized by rapid expansion in both supply and demand. Investments in plasma collection facilities in China and India are augmenting global plasma reserves, and government‐led immunology programs are accelerating patient access. Meanwhile, diversification of distribution networks and partnerships with multinational biologics firms are facilitating broader deployment of gamma globulin therapies across urban and rural settings.

Discovering the Strategic Positioning and Growth Trajectories of Leading Companies Innovating in Gamma Globulin Therapeutic Development and Commercialization

Leading companies in the gamma globulin therapeutics market have demonstrated strategic agility through targeted acquisitions, research collaborations, and capacity expansions. CSL Behring has fortified its portfolio with novel hyperimmune products and enhanced fractional yields via state-of-the-art manufacturing facilities, securing its position as a global leader. Grifols has pursued geographic diversification, establishing new plasma centers in key regions while deepening its investment in recombinant immunoglobulin research.

Takeda has focused on lifecycle management, optimizing existing immunoglobulin formulations and exploring innovative delivery mechanisms to extend market reach. Octapharma has adopted a patient-centric model, integrating digital adherence tools with subcutaneous options to drive home administration uptake. Biotest continues to refine its immunotherapy pipeline through targeted R&D efforts and strategic partnerships with academic institutions. These market leaders are leveraging complementary competencies-ranging from supply chain integration to advanced analytics-to outpace competition and anticipate emerging clinical needs.

Formulating Actionable Recommendations to Equip Industry Leaders With Tactical Insights and Strategic Roadmaps for Advancing Gamma Globulin Innovations

Company executives should prioritize strategic investments in advanced fractionation processes and recombinant antibody platforms to sustain long-term competitive differentiation. By forging partnerships with clinical research organizations, organizations can accelerate proof-of-concept studies and expand into novel therapeutic indications. In addition, adopting outcome-based contracting models with payers will align pricing structures with real-world effectiveness, fostering value recognition in budget-constrained environments.

To address supply challenges, diversifying plasma sourcing through regional collection initiatives and public-private collaborations will mitigate tariff and geopolitical risks. Equally important is the development of robust patient support programs that integrate digital monitoring with educational resources, enhancing adherence and generating longitudinal data on treatment outcomes. Finally, strengthening regulatory engagement through early dialogue and coordinated submissions can expedite approvals for new formulations and administration routes, ensuring faster patient access and optimized commercial roll-out.

Outlining Robust Research Methodology Employed to Ensure Data Integrity Analytical Rigor and Actionable Insights in Gamma Globulin Therapeutics Market Analysis

This analysis is founded on a rigorous, multi-method research approach that combines comprehensive secondary research with targeted primary investigations. Global regulatory databases and peer-reviewed journals served as the cornerstone for verifying clinical and manufacturing developments, while proprietary databases provided historic pricing and distribution channel intelligence. Expert interviews with key opinion leaders, including clinicians, regulatory advisors, and supply chain specialists, enriched the qualitative dimension of the study.

Quantitative insights were obtained through synthesis of company financial disclosures, trade publications, and anonymized survey data from end users, enabling validation of demand drivers and adoption curves. Advanced analytics, including scenario modeling and sensitivity testing, were applied to assess the impact of tariff changes and segment variations. Data triangulation ensured consistency across sources, and iterative validation workshops with industry stakeholders further refined the strategic recommendations presented herein.

Concluding Insights Emphasizing Strategic Imperatives to Propel the Gamma Globulin Therapeutics Market Into Its Next Phase of Growth

The evolving gamma globulin therapeutics market presents a confluence of scientific innovation, regulatory complexity, and shifting payer landscapes. Strategic imperatives for stakeholders include deepening investments in precision immunotherapies, fortifying supply chain resilience against tariff fluctuations, and leveraging segmentation intelligence to unlock new growth pockets. Regional variations underscore the need for adaptive commercialization strategies, while competitive dynamics highlight the value of strategic collaborations and technology integration.

Looking ahead, embracing patient-centric care models and outcome-linked pricing will define market leadership, as healthcare systems and payers demand transparent value demonstration. By aligning clinical innovation with real-world evidence generation and regulatory foresight, industry participants can navigate uncertainties and drive sustainable expansion. This conclusion synthesizes critical insights from across the report, equipping decision-makers with the strategic vision required to shape the next frontier in gamma globulin therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Hyperimmune Globulin
    • Standard Immunoglobulin
  • Application
    • Autoimmune Disease
    • Primary Immune Deficiency
    • Secondary Immune Deficiency
  • Administration Route
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • CSL Behring LLC
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Biotest AG
  • Bio Products Laboratory Ltd
  • Sanquin Plasma Products Foundation
  • Shanghai RAAS Blood Products Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of subcutaneous immunoglobulin therapies in home care settings
5.2. Emergence of biosimilar immunoglobulin products intensifying market competition dynamics
5.3. Impact of plasma donor shortages on gamma globulin therapeutic agent availability and pricing
5.4. Growing investment in recombinant immunoglobulin production to ensure scalable supply chains
5.5. Shifting reimbursement policies influencing patient access to high-cost immunoglobulin therapies
5.6. Integration of digital infusion pump technologies enhancing safety and dosing precision during IVIG administration
5.7. Strategic collaborations between biotech firms and plasma collection centers to secure raw material sources
5.8. Expansion of gamma globulin applications in emerging infectious disease prophylaxis and treatment pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gamma Globulin Therpeautic Agent Market, by Product Type
8.1. Introduction
8.2. Hyperimmune Globulin
8.3. Standard Immunoglobulin
9. Gamma Globulin Therpeautic Agent Market, by Application
9.1. Introduction
9.2. Autoimmune Disease
9.3. Primary Immune Deficiency
9.4. Secondary Immune Deficiency
10. Gamma Globulin Therpeautic Agent Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Gamma Globulin Therpeautic Agent Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Gamma Globulin Therpeautic Agent Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Gamma Globulin Therpeautic Agent Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gamma Globulin Therpeautic Agent Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gamma Globulin Therpeautic Agent Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Behring LLC
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. LFB S.A.
16.3.7. Biotest AG
16.3.8. Bio Products Laboratory Ltd
16.3.9. Sanquin Plasma Products Foundation
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET: RESEARCHAI
FIGURE 26. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET: RESEARCHSTATISTICS
FIGURE 27. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET: RESEARCHCONTACTS
FIGURE 28. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY SECONDARY IMMUNE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY SECONDARY IMMUNE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 71. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 76. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 77. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. CANADA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 86. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 87. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. MEXICO GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. UNITED KINGDOM GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 138. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 139. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. GERMANY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. FRANCE GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. RUSSIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. ITALY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 178. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 179. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. SPAIN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. SAUDI ARABIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SOUTH AFRICA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 218. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 219. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. DENMARK GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. NETHERLANDS GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 238. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 239. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. QATAR GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 248. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 249. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. FINLAND GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. SWEDEN GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. NIGERIA GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. EGYPT GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 286. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 287. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 288. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 289. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. TURKEY GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL GAMMA GLOBULIN THERPEAUTIC AGENT MARKET SIZE, BY ADMINISTRATION

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gamma Globulin Therpeautic Agent market report include:
  • CSL Behring LLC
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • LFB S.A.
  • Biotest AG
  • Bio Products Laboratory Ltd
  • Sanquin Plasma Products Foundation
  • Shanghai RAAS Blood Products Co., Ltd.

Related Topics

Related Reports

Gamma Globulin Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Gamma Globulin Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 84 Pages
  • Global
From
Hyperimmune Globulin Product Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Hyperimmune Globulin Product Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030 - Product Image

Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Hyperimmune Globulins Market Report 2025 - Product Image

Hyperimmune Globulins Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Human Tetanus Immune Globulin (HTIG) Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type - Product Image

Human Tetanus Immune Globulin (HTIG) Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 86 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.